Mindray became the general agent of GenSure Biotech’ SARS-CoV-2 antigen test

According to industry insiders, Mindray became the general agent of GenSure Biotech Inc., and officially started entered the SARS-CoV-2 antigen test business.

On April 20, the SARS-CoV-2 (2019-nCOV) antigen test kit (latex method) produced by GenSure Biotech Inc. got NMPA certification issued by the National Medical Products Administration and was officially approved for sale.

The product uses latex immunochromatography technology to detect the SARS-CoV-2 (2019-nCoV) N protein antigen in human nasal swabs based on the principle of double antibody sandwich method. The sensitivity of the product is 96.86%, the specificity is 100%, and the accuracy is 98.78%.

Chen Qingquan, founder and CEO of GenSure Biotech Inc., holds a Ph.D. in virology. The R&D team led by Dr. Chen has accumulated rich experience in the process of protein recombinant expression, virus culture, preparation and purification of monoclonal and polyclonal antibodies, paired screening, and small molecule synthesis.

Since the outbreak of the epidemic, Mindray has not actively deployed in the field of COVID-19 related reagents, and overseas relevant sales are also relatively small. Meanwhile, many IVD companies develop rapidly based the opportunities of COVID-19. In the first quarter of 2022 alone, the net profit of Andon Health and Assure Tech exceeded that of Mindray.

Mindray's cooperation with GenSure this time is relatively low-key, and Mindray officials have not issued a public statement yet.

About GenSure

GenSure Biotech Inc. is a high-tech company established in 2016. It has served the global Rapid Testing Devices market extensively with our COVID-19 Rapid Test Kits. We, now with presence in Beijing, Shanghai and Shijiazhuang, China, have expanded in capacity, size, and product range and risen to be a Top-10 exporter and OEM manufacturer of COVID-9 Rapid Test Kits, boasting most POCT product lines in China.